What should I know about Insmed?
Insmed is a US biopharmaceutical company, headquartered in Bridgewater, New Jersey, that develops treatments for serious and rare diseases, with a focus on lung conditions. Its second-quarter 2026 report describes three areas of work: respiratory, immunology and inflammation, and neurology and other rare diseases. Insmed sells two medicines and runs a pipeline that includes inhaled drugs, antibodies and gene therapies. The company trades on the Nasdaq under the ticker INSM.
What are Insmed's main drugs?
[Answer] Insmed has two marketed medicines. Brinsupri (brensocatib) is a once-daily tablet approved for non-cystic fibrosis bronchiectasis, a chronic lung condition, in people aged 12 and over. It is approved in the US, EU and UK. According to the Q2 2026 report, Brinsupri sold $309.2 million in the quarter. Arikayce, an inhaled antibiotic for a hard-to-treat lung infection, sold $116.3 million. Insmed expects 2026 Brinsupri sales of $1.25 billion to $1.40 billion and Arikayce sales of $450 million to $470 million.
What is Insmed currently developing?
Insmed's lead development drug is TPIP (treprostinil palmitil inhalation powder), which is in Phase 3 trials for pulmonary arterial hypertension and for pulmonary hypertension linked to interstitial lung disease. Further Phase 3 studies in pulmonary fibrosis are planned. The Q2 2026 report also lists INS1148, an antibody in Phase 2; INS1033, a rheumatoid arthritis candidate cleared for first-in-human trials; and gene therapies for Duchenne muscular dystrophy and ALS in Phase 1. Japan's decision on brensocatib is expected in the second half of 2026.
Is Insmed publicly traded, and how big is it?
Yes. Insmed trades on the Nasdaq under the ticker INSM. Its market capitalisation was about $21.9 billion at the 8 October 2026 close, and another tracker put it near $24.3 billion on 2 October 2026. Total revenue for the second quarter of 2026 was $425.5 million, up from $107.4 million a year earlier.